2021年5月26日讯/生物谷/BIOON/---近日,澳门科技大学在Gut杂志上发表了题为"Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti- PD-1/PD- L1) immunotherapy"的研究性文章。
原名:Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/ programmed cell death ligand1 (anti-PD- 1/PD-L1) immunotherapy 译名:人参多糖改变肠道菌群和犬尿氨酸/色氨酸比例,增强抗程序性细胞死亡1 /程序性细胞死...
Salama AK, Kang Y, Hsu D, Balko JM, Johnson DB,Starr M, Nixon A, Holtzhausen A, Hanks BA. A tumor-intrinsic PD-L1/NLRP3inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy. JClin Invest. 202...
Anti-PD-1 immunotherapy with adjuvant ablative fractional laser displays increased tumour clearance of squamous cell carcinoma, a murine study PD-1 checkpoint inhibitors are used as systemic immunotherapy for locally advanced and metastatic cutaneous squamous cell carcinoma (SCC); however, improve... RL...
Aparadigm of cancer immunotherapy based on 2-[18F]FDG and anti-PD-L1mAb combination to enhance the anti-tumor effect 合作单位:厦门大学公共卫生学院发表杂志:Clinical Cancer Research(IF:12.531)发表时间:2022年3月23日 研究背景 目前,免疫治疗已成为继手术、放疗、化疗后的第四大肿瘤治疗疗法,主要包括免疫...
immunotherapyglycopeptideIgGImmune checkpoint inhibitors (ICIs) targeting programmed cell death 1/programmed cell death ligand-1 (PD-1/PD-L1) have significantly prolonged the survival of advanced/metastatic patients with lung cancer. However, only a small proportion of patients can benefit from ICIs, ...
These findings suggest that targeting ALKBH5 is a promising strategy of enhancing the anti-tumor immune response in patients with NSCLC and that identifying ALKBH5 status could facilitate prediction of clinical response to anti-PD-L1 immunotherapy....
The novel antibody-based immunotherapy in oncology exploits the activation of immune system mediated by immunomodulatory antibodies specific for immune checkpoints. Among them, the programmed death ligand-1 (PD-L1) is of particular interest as it is expr
FcγR interaction is not required for effective anti-PD-L1 immunotherapy but can add additional benefit depending on the tumor model FcgammaR interaction is not required for effective anti-PD-L1 immunotherapy but can add additional benefit depending on the tumor model. Int. J. Cancer ... HS ...
Immunotherapy, especially anti-programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) treatment has significantly improved the survival of non-small cell lung cancer (NSCLC) patients. However, the overall response rate remains unsati